Simbrinza eye drops 5ml — Made in Belgium — Free Delivery

Product description

Eye drops "Simbrinza®" are used to reduce increased intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension, in whom monotherapy did not lead to a sufficient decrease in intraocular pressure.

Composition

1 ml of suspension contains (active ingredients):

brinzolamide - 10 mg;

brimonidine tartrate - 2 mg.

Excipients: benzalkonium chloride, propylene glycol, carbomer 974P, boric acid, beckon (E 421), sodium chloride, tyloxapol, hydrochloric acid and / or sodium hydroxide (for pH adjustment), purified water.

Contraindications

• hypersensitivity to active substances or to any of the components of the preparation ;
• the use of monoamine oxidase (MAO) inhibitors;
• the use of antidepressants that affect noradrenergic transmission (for example, tricyclic antidepressants and mianserin);
• severe renal dysfunction;
• hyperchloremic acidosis;
• newborns and infants under 2 years of age.

Mode of application

For adults, including elderly patients: the recommended dose is one drop of the preparation in the affected eye (s) 2 times a day.

Method of use

For ophthalmic use. The patient should be advised to shake the bottle well before use. Systemic absorption is reduced if you press on the nasolacrimal opening or close the eyelids for two minutes. This reduces systemic adverse reactions and increases local activity. To prevent contamination of the dropper tip and the contents of the bottle, care must be taken not to touch the eyelids or other surfaces with the tip of the dropper bottle. Patients should be advised to close the bottle tightly after applying the drops.

The preparation "Simbrinza®" can be used simultaneously with other ophthalmic preparations of local action to reduce intraocular pressure. If more than one ophthalmic agent is applied topically, the interval between their application should be at least 5 minutes.

If a dose has been missed, treatment must be continued with the next dose according to the treatment regimen. The dose should not exceed one drop in the affected eye (s) twice a day.

Application features

Pregnant

Data on the use of the preparation in pregnant women are not available or their number is limited. It is not recommended to prescribe during pregnancy and women of reproductive age who do not use contraceptives.

The preparation is not recommended for women during breastfeeding.

No effect of brinzolamide or brimonidine on reproductive function during preclinical studies was not revealed. There are no data on the effect of the preparation on the human body when applied topically.

Children

The safety and efficacy of the preparation in children aged 2 to 18 years have not been established. There are no data on the use of the preparation in children. The preparation is not recommended for use in children. For safety reasons, the preparation is contraindicated for the treatment of newborns and infants under the age of 2 years.

Drivers

The preparation may cause dizziness, fatigue and / or drowsiness, which may affect the ability to drive and operate other mechanisms.

Temporary blurred vision or other visual impairments can adversely affect the ability to drive or operate machinery. If blurred vision occurs during instillation, the patient should wait until vision is restored, and only then drive vehicles or work with other mechanisms. Oral carbonic anhydrase inhibitors may impair the ability to perform activities that require mental focus and / or physical coordination in the elderly.

Overdose

In case of preparation overdose, treatment should be symptomatic and supportive. Adequate airway should be maintained for the patient.

Due to the presence of brinzolamide in the composition of the preparation, electrolyte imbalance, acidosis and disorders of the nervous system may occur. In such cases, it is necessary to monitor the level of electrolytes in the blood serum (especially potassium) and blood pH.

There is very limited data on the effects of accidental ingestion of a component of the brimonidine preparation by adults. At present, only such an adverse reaction as a decrease in blood pressure has been reported. It was also reported that after an episode of hypotension, a rebound effect was observed in the form of hypertension.

Serious side effects have been reported in children after accidental ingestion of brimonidine, which is part of the preparation. The patients showed symptoms of CNS depression, circulating coma or depression of consciousness, lethargy, drowsiness, hypotension, bradycardia, hypothermia, pallor, respiratory failure and apnea, which required intensive therapy with intubation if necessary. It was reported that usually all patients recovered completely within 6-24 hours.

Side effects

During clinical trials of the preparation, when applied twice a day, the most common adverse reactions were eye flushing and allergic-type reactions from the visual organs, which occurred in about 6-7% of patients, and dysgeusia (a bitter or unusual taste in the mouth after instilling the preparation). which was observed in 3% of patients.

Storage conditions

Does not require special storage conditions.

Shelf life - 2 years (after the first opening of the bottle - 4 weeks).